Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Abstract Text:

    Fibromyalgia syndrome is a systemic disorder of widespread pain which is thought to result from abnormal pain processing within the central nervous system. There are no currently approved treatments for this indication. Antidepressants appear, however, to be effective, especially those with an action on noradrenergic neurotransmission. The objective of the present study was to test the efficacy of the dual action noradrenaline and serotonin reuptake inhibitor antidepressant, milnacipran, in the treatment of fibromyalgia. The 125 patients, who were enrolled in a double-blind, placebo-controlled, flexible dose escalation trial, were randomized to receive placebo or milnacipran for 4 weeks of dose escalation (up to 200 mg/day), followed by 8 weeks at a constant dose. The study evaluated the efficacy and safety of milnacipran for the treatment of pain and associated symptoms such as fatigue, depressed mood and sleep. 75% of milnacipran-treated patients reported overall improvement, compared with 38% in the placebo group (p < 0.01). Furthermore, 37% of twice daily milnacipran-treated patients reported at least 50% reduction in pain intensity, compared with 14% of placebo-treated patients (p < 0.05). 84% of all milnacipran patients escalated to the highest dose (200 mg/day) with no tolerability issues. Most adverse events were mild to moderate in intensity, and transient in duration. These results suggest that milnacipran may have the potential to relieve not only pain but several of the other symptoms associated with fibromyalgia.

    A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Publishing Authors By Initials

    For similar behavior and behavior mechanisms: behavior: health behavior: patient compliance research abstracts see: behavior and behavior mechanisms: behavior: health behavior: patient compliance research

    PUBMED ID PMID:

    MEDLINE DATE:

    A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Journal Published:

    PUBLICATION TYPE: Randomized Controlled Trial

    Journal: Human psychopharmacology

    VOLUME: 19 Suppl 1

    Page Numbers: S27-35

    Journal Abbreviation: Hum Psychopharmacol

    ISSN: 0885-6222

    DAY: 6

    MONTH: Oct

    YEAR: 2004

    A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8702539

    A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Keywords Mesh Terms:

    KEYWORDS: Patient Compliance

    MESH TERMS: physiopathology

    Chemical & Substance for Abstract: A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Information

    Substance Name: milnacipran

    Registry Number: 92623-85-3

    Grant and Affiliation Information for A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.

    AFFILIATION: Cypress Bioscience, San Diego, CA 9212, USA. ovitton@cypressbio.com

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Hum Psychopharmacol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News